Hike Medical Raises $22.5M for Device-Based Care

A custom medical device can be clinically necessary and still spend weeks trapped between a fax queue, a payer checklist, a scanning tool, and a fabrication bench. Hike Medical has raised $22.5M across Seed and Series A financing to make one company accountable for more of that journey.

The financing was led by Saga Ventures through Max Altman, with participation from Indicator Ventures, Fifth Down Capital, RiverPark Ventures, strategic investor and commercial partner Orthofeet, and named angels including Sam Blond and Jerod Mayo. Hike plans to use the capital to expand engineering and sales in San Francisco, manufacturing in Peoria, Illinois, and its reach beyond custom insoles into the wider durable medical equipment market.

What Hike Medical announced

The August 25, 2026 funding announcement combines Hike Medical's Seed and Series A financings. The company did not disclose how much belonged to either round, the date of each close, or a valuation, so the event should not be read as one new $22.5M Series A.

That distinction matters because round labels create a false sense of precision when the underlying capital record is aggregated. The verified fact is that Hike has raised $22.5M across the two early-stage rounds and now has fresh public permission to scale the operating model those rounds financed.

Alongside Saga, the syndicate includes Indicator Ventures, Fifth Down Capital, and RiverPark Ventures. Orthofeet joined as both a strategic investor and commercial partner. The combination of venture firms, an industry company, and operator angels suggests that the investment case reaches beyond software margins into distribution, manufacturing, and execution.

Why the device workflow is the real market

Hike co-founder and CEO Aadi Bhanti comes from three generations of orthotics and prosthetics clinicians. That background gave the company a view of the parts of device delivery that a horizontal software vendor can miss: the referral fax, incomplete clinical documentation, payer requirements, a physical scan, fabrication, fitting, billing, and the patient waiting at the end.

Hike says tens of millions of Americans use devices such as diabetic inserts, braces, prosthetic limbs, wheelchairs, and cranial helmets inside a category representing roughly $100B in annual spending. The company also says 60 cents of every dollar is lost to waste, remakes, and fraud. Those figures come from Hike's research and are not independently audited, but the workflow problem is visible across the company's product design: each handoff adds another opportunity for delay, denial, rework, or missing information.

The economic opportunity is therefore not limited to making a better insole or reading a fax faster. It is the gap between a clinical decision and a correctly manufactured device that arrives with enough documentation to be approved, dispensed, and paid for.

How Hike connects software to manufacturing

Hike is building three connected operating layers. Hike Intelligence uses AI agents to process incoming referrals, extract patient information, request missing documents, and validate files against device and payer requirements. Hike Clinical gives providers one workflow for evaluation, documentation, smartphone scanning, and ordering.

Hike Lab completes the physical side of the chain. The Peoria operation 3D prints custom devices in-house, allowing the data captured during evaluation to move directly into manufacturing instead of being handed to a disconnected outside lab. Hike says its approach has moved custom-insole production from weeks to days and reduced remake rates from 1 in 15 to 1 in 400. Those are company-reported performance claims, but they define the standard against which the expansion should be measured.

The model asks Hike to own problems that software companies often prefer to leave to customers or partners. Manufacturing yield, clinical quality, payer compliance, logistics, and service operations now sit beside model performance and product usability. Vertical integration can remove handoffs, but it also makes every failed handoff the company's own.

Why investors are backing vertical integration

Saga Ventures co-founder and managing partner Max Altman framed Hike as the kind of company that can rebuild a broken industry by owning the value chain rather than placing another software layer on top. That logic fits the physical nature of device-based care. A document agent can reduce administrative work, but it cannot fabricate, fit, or deliver a device.

The investment thesis depends on those layers becoming more valuable together. Better referral data can improve the clinical visit. Better clinical data can reduce manufacturing error. A controlled lab can shorten feedback loops and expose which scans, documentation patterns, and device designs produce better operational results.

That loop is difficult to copy because it requires software talent, clinical understanding, payer knowledge, and physical production under one operating system. It is also expensive to scale. The $22.5M gives Hike more capacity to prove that the integration creates durable service and unit-economics advantages instead of simply accumulating complexity.

What the capital makes possible

Hike plans to hire engineers and salespeople in San Francisco and expand manufacturing in Peoria. The company is also moving beyond custom insoles into broader orthotics, prosthetics, and durable medical equipment categories, where documentation, reimbursement, device design, and clinical workflows can vary substantially.

CTO Nik Varshney is responsible for the technical layer, while COO Jerry Tang brings experience from Flexport and digital dental lab Dandy to the scaling problem. Their work now has to connect software reliability with factory discipline. A fast AI workflow is useful only when the physical product arrives correctly and the evidence supporting it survives payer scrutiny.

The company has not disclosed a device-category roadmap, revenue run rate, customer concentration, or independently audited quality data. Those gaps do not erase the opportunity, but they define the diligence questions that matter after the funding headline.

What Hike Medical has to prove next

Hike's next phase is a test of transferability. Custom insoles gave the company a contained device category in which to connect scanning, documentation, and 3D printing. Expanding into additional DME categories introduces different clinical decisions, coding requirements, materials, manufacturing processes, and consequences when a device is wrong.

The company must show that the same operating system can absorb that variation without surrendering the turnaround and remake-rate improvements it reports today. It also has to prove that providers will trust one platform with administrative, clinical, and manufacturing work that has historically been distributed across multiple vendors and teams.

For healthcare operators, the important signal is not another AI funding round. It is that investors are financing control of the physical workflow, where reimbursement and patient experience meet. Hike Medical now has $22.5M across Seed and Series A capital to prove that owning more of the path can put the right device on a patient faster without making the system harder to trust.